title: Partial Response and Cardiovascular Recovery  after Sorafenib Dose Reduction in a Multinodular  HCC Patient.
authors: Rodolfo
authors: R
authors: Sacco
authors: Irene
authors: I
authors: Bargellini
authors: Barbara
authors: B
authors: Ginanni
authors: Marco
authors: M
authors: Bertini
authors: Elena
authors: E
authors: Bozzi
authors: Emanuele
authors: E
authors: Altomare
authors: Valentina
authors: V
authors: Battaglia
authors: Antonio
authors: A
authors: Romano
authors: Emanuele
authors: E
authors: Tumino
authors: Matteo
authors: M
authors: Di Biase
authors: Giampaolo
authors: G
authors: Bresci
authors: Carlo
authors: C
authors: Bartolozzi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011379:Prognosis; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib